Slide Show: Gastrointestinal Stromal Tumors

The regulatory agency has set a Prescription Drug User Fee Act date of February 7, 2024 for pembrolizumab plus chemotherapy as a treatment for patients with advanced or metastatic biliary tract cancer.

Tanios Bekaii-Saab, MD, details the GOZILA platform for colorectal cancer with experts Kristen Ciombor, MD, MSCI, and John Strickler, MD.

Cabozantinib plus nivolumab and ipilimumab appears to improve progression-free survival vs cabozantinib alone among patients with metastatic soft-tissue sarcoma in a phase 2 trial.

Tanios Bekaii-Saab, MD, sits with Kristen Ciombor, MD, MSCI, and John Strickler, MD, to examine the COLOMATE platform for patients with colorectal cancer.

Results from the phase 2b HERIZON-BTC-01 trial show positive efficacy and safety responses in patients with locally advanced, unresectable or metastatic biliary tract cancer.

Manufacturers plan to halt further development of milademetan for liposarcoma following the publication of topline results from the phase 3 MANTRA trial.